Incretin weight loss in type 1 diabetes

A prospective observational study followed 70 adults with obesity and type 1 diabetes for 12 months after they started liraglutide, semaglutide, or tirzepatide in routine obesity care. Average body weight fell, as did fat mass and lean mass. Total-body bone mineral density did not change significantly. The study can describe those changes, but it cannot prove that a particular medicine caused them or establish which of the three treatments performed best^[1].

What the researchers measured

The body-composition question fills a gap left by the wider literature. A systematic review of research in adults with type 1 diabetes and overweight or obesity found lower body weight and HbA1c with GLP-1 receptor agonist treatment, but it did not establish what happened to body tissues or bone^[3]. The new study used scans to examine those separate compartments.

The participants received care at the Dasman Diabetes Institute in Kuwait, and all were of Arab ethnicity. Their mean age was 36.7 years. Mean body mass index was 31.7 kg/m², while mean HbA1c was 8.3% at baseline. HbA1c reflects average blood glucose over roughly the previous two to three months. Most participants used liraglutide: 49 of 70, compared with 13 using semaglutide and eight using tirzepatide^[1]. This imbalance matters because the paper reports the cohort together rather than presenting a powered comparison among the medicines.

Body composition was assessed at baseline and 12 months with dual-energy X-ray absorptiometry, usually shortened to DXA. The scans estimated total and regional fat mass, lean mass, bone mineral content, and total-body bone mineral density. Electronic health records supplied body weight, HbA1c, treatment discontinuation, severe hypoglycaemia, and diabetic ketoacidosis data^[1]. DXA lean mass is not a direct measurement of muscle strength or physical function, so a change in the scan result should not be treated as proof of functional decline.

The 12-month changes

Across the full cohort, body weight decreased by 6.33%, with a 95% confidence interval from 4.73% to 7.92% lower. Total fat mass decreased by 5.90%, while total lean mass decreased by 1.75%. HbA1c fell by 0.48 percentage points. These analyses were adjusted for age and sex, and each change was statistically significant^[1]. The larger relative reduction in fat mass than lean mass is useful context, but the study did not report strength, mobility, or other functional outcomes.

Total-body bone mineral content and bone mineral density showed no statistically significant change at 12 months. That is narrower than saying bone health was proven safe. The authors note that total-body DXA may miss changes at the hip or spine, that 12 months may be too short to detect a difference, and that large changes in body size can affect DXA estimates^[1]. No fractures were reported as a study endpoint. The result is therefore reassuring within the measurement used, not a final answer about long-term skeletal risk.

Why the amount of weight loss mattered

The researchers also grouped participants by weight loss. Among 32 people who lost less than 5%, no significant changes appeared in body weight, HbA1c, total fat mass, total lean mass, bone mineral content, or bone mineral density. Seventeen people lost 5% to 10%; this group had lower body weight, total fat mass, and HbA1c, without a significant change in total lean mass or the bone measures. The 21 people who lost more than 10% had a 14.42% weight reduction, a 19.0% fall in total fat mass, and a 3.47% fall in total lean mass^[1].

The lean-mass result needs careful wording. A significant decline appeared within the group that lost more than 10% of body weight, but the difference in lean-mass change across the three weight-loss groups was not statistically significant (p = 0.114). Weight loss correlated with both fat-mass loss and lean-mass loss, with a stronger reported relationship for fat mass^[1]. These exploratory subgroup findings can guide future trials. They do not define a threshold at which lean tissue will decline for an individual.

What this study cannot compare

This was not a randomised trial and had no untreated control group. Treatment choice came from routine care, and the three medicine groups were small and uneven. The paper therefore cannot separate medicine effects from differences in diet, activity, insulin use, illness, or the characteristics that influenced treatment selection. Dietary intake, physical activity, and changes in insulin dose were not available^[1]. A separate 250-person observational report from the same research group compared weight and metabolic outcomes across the three medicines and usual care, but it did not supply a randomised comparison or answer the DXA questions in this study^[4]. Readers should not use these pooled results to rank liraglutide against semaglutide or tirzepatide. Our semaglutide research overview and tirzepatide evidence guide keep evidence for each molecule separate.

The safety observation was limited too. The records contained no reported severe hypoglycaemia or diabetic ketoacidosis during follow-up, but the study did not collect a full adverse-event set. Gastrointestinal symptoms and other events were not captured^[1]. Absence of those two severe events in 70 people is not evidence that treatment carries no risk, particularly in a population managing insulin.

What we do not yet know

A larger randomised study would need a suitable comparator, enough participants to evaluate each medicine, prespecified body-composition outcomes, and direct measures of strength and physical function. Longer follow-up with hip and spine bone-density measurements would give a better view of skeletal effects. Broader recruitment would also show whether the findings apply beyond this single-centre Arab cohort^[1].

For now, the paper supports a limited conclusion. In this cohort, greater weight loss was accompanied mainly by fat loss, with a smaller lean-mass reduction and no detectable change in total-body bone density over 12 months. It does not show that one incretin medicine is preferable, and it does not provide a treatment plan for type 1 diabetes. Anyone considering an obesity medicine while using insulin should discuss the evidence and personal monitoring with a qualified clinician^[1].